Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10264)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
SIRT2
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Responsed Disease | Multiple myeloma | ICD-11: 2A83 | |||
Responsed Drug | Ginsenoside Rh4 | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell apoptosis | |||||
Cell cycle | |||||
In Vitro Model |
NCI-H929 cells | Plasma cell myeloma | Homo sapiens | CVCL_1600 | |
Response regulation | Ginsenoside Rh4 inhibited SIRT2 expression in multiple myeloma (MM) cells. The overexpression of SIRT2 reversed the effects of ginsenoside Rh4 on cell proliferation, cell apoptosis, cycle arrest and ferroptosis in MM. Overall, ginsenoside Rh4 inhibited the malignant progression of MM and induced ferroptosis by regulating SIRT2. | ||||
Experiment 2 Reporting the Ferroptosis Target of This Regulator | [3] | ||||
Responsed Disease | Traumatic brain injury | ICD-11: NA07 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
hBCs (Brain cells) | ||||
In Vivo Model |
The Experimental Animal Center at Southern Medical University provided the wild-type (WT) adult male and female C57BL/6 mice (body weight, 22-25 g). Briefly, mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (30 mg/kg), and mounted on a stereotaxic frame. A midsagittal incision was made in the scalp and a circular craniotomy (4.5 mm diameter) was made over the left parietotemporal cortex.
Click to Show/Hide
|
||||
Response regulation | P53-mediated ferroptosis contributes to the pathogenesis of traumatic brain injury (TBI). Furthermore, SIRT2 exerts a neuroprotective effect against TBI by suppressing p53-mediated ferroptosis. | ||||
Solute carrier family 40 member 1 (SLC40A1) [Suppressor; Marker]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Neuropathic pain | ICD-11: 8E43 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vivo Model |
About 70 adult male Sprague-Dawley rats weighing 200-250 g were used in the animal model. Rats were anesthetized with 5% isoflurane by a small animal anesthesia machine and maintained with 2-3% isoflurane. The rats were placed in a left decubitus position; approximately 1 cm below the right iliac bone, the three branches of the sciatic nerve were exposed: the tibial nerve, common peroneal nerve, and sural nerve.
Click to Show/Hide
|
||||
Response regulation | An intrathecal injection of SIRT2 overexpressed recombinant adenovirus, which upregulated the expression of SIRT2, attenuated mechanical allodynia, enhanced the level of FPN1, inhibited intracellular iron accumulation, and reduced oxidant stress levels, thereby reversing the changes to ACSL4 and GPX4 expression in the SNI rats. This evidence suggests that SIRT2-targeted therapeutics may help relieve the symptoms of chronic neuropathic pain (NP). | ||||
Multiple myeloma [ICD-11: 2A83]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | NAD-dependent protein deacetylase sirtuin-2 (SIRT2) | Protein coding | ||
Responsed Drug | Ginsenoside Rh4 | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
Cell apoptosis | ||||
Cell cycle | ||||
In Vitro Model |
NCI-H929 cells | Plasma cell myeloma | Homo sapiens | CVCL_1600 |
Response regulation | Ginsenoside Rh4 inhibited SIRT2 expression in multiple myeloma (MM) cells. The overexpression of SIRT2 reversed the effects of ginsenoside Rh4 on cell proliferation, cell apoptosis, cycle arrest and ferroptosis in MM. Overall, ginsenoside Rh4 inhibited the malignant progression of MM and induced ferroptosis by regulating SIRT2. | |||
Neuropathic pain [ICD-11: 8E43]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | NAD-dependent protein deacetylase sirtuin-2 (SIRT2) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vivo Model |
About 70 adult male Sprague-Dawley rats weighing 200-250 g were used in the animal model. Rats were anesthetized with 5% isoflurane by a small animal anesthesia machine and maintained with 2-3% isoflurane. The rats were placed in a left decubitus position; approximately 1 cm below the right iliac bone, the three branches of the sciatic nerve were exposed: the tibial nerve, common peroneal nerve, and sural nerve.
Click to Show/Hide
|
||||
Response regulation | An intrathecal injection of SIRT2 overexpressed recombinant adenovirus, which upregulated the expression of SIRT2, attenuated mechanical allodynia, enhanced the level of FPN1, inhibited intracellular iron accumulation, and reduced oxidant stress levels, thereby reversing the changes to ACSL4 and GPX4 expression in the SNI rats. This evidence suggests that SIRT2-targeted therapeutics may help relieve the symptoms of chronic neuropathic pain (NP). | ||||
Traumatic brain injury [ICD-11: NA07]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [3] | ||||
Target Regulator | NAD-dependent protein deacetylase sirtuin-2 (SIRT2) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
hBCs (Brain cells) | ||||
In Vivo Model |
The Experimental Animal Center at Southern Medical University provided the wild-type (WT) adult male and female C57BL/6 mice (body weight, 22-25 g). Briefly, mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (30 mg/kg), and mounted on a stereotaxic frame. A midsagittal incision was made in the scalp and a circular craniotomy (4.5 mm diameter) was made over the left parietotemporal cortex.
Click to Show/Hide
|
||||
Response regulation | P53-mediated ferroptosis contributes to the pathogenesis of traumatic brain injury (TBI). Furthermore, SIRT2 exerts a neuroprotective effect against TBI by suppressing p53-mediated ferroptosis. | ||||
Ginsenoside Rh4
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Unspecific Target | |||
Responsed Disease | Multiple myeloma | ICD-11: 2A83 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Ferroptosis | hsa04216 | |||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
Cell apoptosis | ||||
Cell cycle | ||||
In Vitro Model |
NCI-H929 cells | Plasma cell myeloma | Homo sapiens | CVCL_1600 |
Response regulation | Ginsenoside Rh4 inhibited SIRT2 expression in multiple myeloma (MM) cells. The overexpression of SIRT2 reversed the effects of ginsenoside Rh4 on cell proliferation, cell apoptosis, cycle arrest and ferroptosis in MM. Overall, ginsenoside Rh4 inhibited the malignant progression of MM and induced ferroptosis by regulating SIRT2. | |||
References